Kevin L. Grove
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kevin L. Grove has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Arian F. Baquero
Obesity Research, Novo Nordisk Research Center Seattle, Seattle, Washington, USA
2 shared publications - Aaron Jeffrey Mercer
Department of Ophthalmology & Visual Sciences, University of Nebraska Medical Center, Omaha, Nebraska 68198-5840, USA
1 shared publication - Alain Juan De Solis
Department of Neuronal Control of Metabolism, Max Planck Institute for Metabolism Research, Cologne, Germany
1 shared publication - Bao Anh Phan
Department of Medicine, University of Washington Medicine Diabetes Institute, Seattle, Washington, USA
1 shared publication Camdin M. Bennett
Obesity Research, Novo Nordisk Research Center Seattle, Seattle, Washington, USA
1 shared publication- Camdin M. Bennett
Division of Diabetes, Obesity & Metabolism, Oregon National Primate Research Center, Beaverton, OR 97006, USA
1 shared publication
Latest Publications
- Open Access
- 8 September 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (17)
Sustained inhibition of NPY/AgRP neuronal activity by FGF1
In rodent models of type 2 diabetes (T2D), central administration of FGF1 normalizes elevated blood glucose levels in a manner that is sustained for weeks or months. Increased activity of NPY/AgRP neurons in the hypothalamic arcuate nucleus (ARC) is implicated in the pathogenesis of hyperglycemia in these animals, and the ARC is a key brain area for the antidiabetic action of FGF1. We therefore sought to determine whether FGF1 inhibits NPY/AgRP neurons and, if so, whether this inhibitory effect is sufficiently durable to offer a feasible explanation for sustained diabetes remission induced by central administration of FGF1. Here, we show that FGF1 inhibited ARC NPY/AgRP neuron activity, both after intracerebroventricular injection in vivo and when applied ex vivo in a slice preparation; we also showed that the underlying mechanism involved increased input from presynaptic GABAergic neurons. Following central administration, the inhibitory effect of FGF1 on NPY/AgRP neurons was also highly durable, lasting for at least 2 weeks. To our knowledge, no precedent for such a prolonged inhibitory effect exists. Future studies are warranted to determine whether NPY/AgRP neuron inhibition contributes to the sustained antidiabetic action elicited by intracerebroventricular FGF1 injection in rodent models of T2D.
- 8 September 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (17)
Open AccessSustained inhibition of NPY/AgRP neuronal activity by FGF1
In rodent models of type 2 diabetes (T2D), central administration of FGF1 normalizes elevated blood glucose levels in a manner that is sustained for weeks or months. Increased activity of NPY/AgRP neurons in the hypothalamic arcuate nucleus (ARC) is implicated in the pathogenesis of hyperglycemia in these animals, and the ARC is a key brain area for the antidiabetic action of FGF1. We therefore sought to determine whether FGF1 inhibits NPY/AgRP neurons and, if so, whether this inhibitory effect is sufficiently durable to offer a feasible explanation for sustained diabetes remission induced by central administration of FGF1. Here, we show that FGF1 inhibited ARC NPY/AgRP neuron activity, both after intracerebroventricular injection in vivo and when applied ex vivo in a slice preparation; we also showed that the underlying mechanism involved increased input from presynaptic GABAergic neurons. Following central administration, the inhibitory effect of FGF1 on NPY/AgRP neurons was also highly durable, lasting for at least 2 weeks. To our knowledge, no precedent for such a prolonged inhibitory effect exists. Future studies are warranted to determine whether NPY/AgRP neuron inhibition contributes to the sustained antidiabetic action elicited by intracerebroventricular FGF1 injection in rodent models of T2D.
- Open Access
- 1 March 2016
- Published by Elsevier in Molecular Metabolism
- Vol. 5 (3) , 198-209
Postnatal undernutrition delays a key step in the maturation of hypothalamic feeding circuits
- 1 March 2016
- Published by Elsevier in Molecular Metabolism
- Vol. 5 (3) , 198-209
Open AccessPostnatal undernutrition delays a key step in the maturation of hypothalamic feeding circuits